



Date de réception : 06/12/2017



ОБЩ СЪД НА ЕВРОПЕЙСКИЯ СЪЮЗ
TRIBUNAL GENERAL DE LA UNIÓN EUROPEA
TRIBUNÁL EVROPSKÉ UNIE
DEN EUROPÆISKE UNIONS RET
GERICHT DER EUROPÄISCHEN UNION
EUROOPA LIIDU ÜLDKOHUS
ΓΕΝΙΚΟ ΔΙΚΑΣΤΗΡΙΟ ΤΗΣ ΕΥΡΩΠΑΪΚΗΣ ΕΝΩΣΗΣ
GENERAL COURT OF THE EUROPEAN UNION
TRIBUNAL DE L'UNION EUROPÉENNE
CÚIRT GHINEARÁLTA AN AONTAIS EORPAIGH
OPĆI SUD EUROPSKE UNIJE
TRIBUNALE DELL'UNIONE EUROPEA

31
EIROPAS SAVIENĪBAS VISPĀRĒJĀ TIESA
EUROPOS SAJUNGOS BENDRASIS TEISMAS
AZ EURÓPAI UNIÓ TÖRVÉNYSZÉKE
II.-QORTI GENERALI TAL-UNJONI EWROPEA
GERECHT VAN DE EUROPESE UNIE
SĄD UNII EUROPEJSKIEJ
TRIBUNAL GERAL DA UNIÃO EUROPEIA
TRIBUNALUL UNIUNII EUROPENE
VŠEOBECNÝ SÚD EURÓPSKEJ ÚNIE
SPLOŠNO SODIŠČE EVROPSKE UNIJE
EUROOPAN UNIONIN YLEINEN TUOMIOISTUIN
EUROPEISKA UNIONENS TRIBUNAL

ORDER OF THE PRESIDENT
OF THE FOURTH CHAMBER OF THE GENERAL COURT

807329

30 November 2017 *

(Intervention — Application for confidential treatment)

In Case T-329/17,

Heidi Hautala,

Benedek Jávor,

Michèle Ravisi,

Bart Staes,

applicants,

v

European Food Safety Authority,

defendant,

supported by

Federal Republic of Germany,

intervener,

- 1 By document lodged at the Court Registry on 21 September 2017, Monsanto Europe NV/SA and Monsanto Company applied for leave to intervene in the

* Langue de procédure : English.

present proceedings in support of the form of order sought by the European Food Safety Authority.

- 2 By document lodged at the Court Registry on 21 September 2017, Cheminova A/S applied for leave to intervene in the present proceedings in support of the form of order sought by the European Food Safety Authority.
- 3 In support of their application, the applicants for leave to intervene submit that they have a direct and existing interest in the outcome of the proceedings insofar as they are among the owners of the studies containing business secrets that could be made public.
- 4 The applications to intervene were served on the main parties pursuant to Article 144(1) of the Rules of Procedure of the General Court. The main parties have not raised any objections.
- 5 As the applications to intervene have been made in accordance with Article 143 of the Rules of Procedure and the applicants for leave to intervene have established an interest in the outcome of the case, the applications must be granted in accordance with the second paragraph of Article 40 of the Statute of the Court of Justice of the European Union, which applies to the procedure before the General Court by virtue of the first paragraph of Article 53 thereof.
- 6 The applicants have requested, pursuant to Article 144(5) and (7) of the Rules of Procedure, that certain confidential information be excluded from the documents communicated to the interveners and have produced, for that purpose, a non-confidential version of the procedural documents in question.
- 7 At this stage, the communication to the interveners of the documents served or to be served on the main parties must therefore be restricted to a non-confidential version. A decision as to whether the application for confidential treatment is well founded shall, if necessary, be taken at a later stage in the light of any objections which may be submitted on that issue.

On those grounds,

THE PRESIDENT OF THE FOURTH CHAMBER OF THE GENERAL COURT

hereby orders:

1. **Monsanto Europe NV/SA, Monsanto Company and Cheminova A/S are granted leave to intervene in Case T-329/17 in support of the form of order sought by the European Food Safety Authority.**
2. **The Registrar shall provide Monsanto Europe, Monsanto Company and Cheminova with a non-confidential version of each procedural document served on the main parties.**

3. **A time-limit shall be fixed for Monsanto Europe, Monsanto Company and Cheminova to submit any objections regarding the application for confidential treatment. The decision on whether that application is well founded is reserved.**
4. **A time-limit shall be fixed for Monsanto Europe, Monsanto Company and Cheminova to submit a statement in intervention, without prejudice to the possibility of supplementing it later, should the need arise, following a decision on whether the application for confidential treatment is well founded.**
5. **Costs are reserved.**

Luxembourg, 30 November 2017.

E. Coulon



Registrar

H. Kanninen



President